TR200401142T4 - Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem. - Google Patents

Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem.

Info

Publication number
TR200401142T4
TR200401142T4 TR2004/01142T TR200401142T TR200401142T4 TR 200401142 T4 TR200401142 T4 TR 200401142T4 TR 2004/01142 T TR2004/01142 T TR 2004/01142T TR 200401142 T TR200401142 T TR 200401142T TR 200401142 T4 TR200401142 T4 TR 200401142T4
Authority
TR
Turkey
Prior art keywords
glp
compound
solution
peptide compounds
aqueous
Prior art date
Application number
TR2004/01142T
Other languages
English (en)
Inventor
Junior Walter Francis Prouty
Junior Joseph Vincent Rinella
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200401142T4 publication Critical patent/TR200401142T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

pH 7.4'de sulu çözelti içinde esas olarak çözünmeyen bir GLP-1 bilesiginden, pH 7.4'de sulu çözelti içinde çözünen bir GLP-1 bilesiginin hazirlanmasi için yöntem anlatilmistir. Çözünmeyen GLP-1 bilesigi bir GLP-1 çözeltisinin olusturulmasi için sulu baz ya da sulu asit içinde çözülmektedir. Sonra, GLP-1 çözeltisi, GLP-1 bilesiginin esas olarak hiç amino asit rasemizasyonunun cereyan atmedigi bir pH'a nötralize edilmekte, sonra, çözünür GLP-bilesigi nötralize edilen çözeltiden izole edilmektedir.
TR2004/01142T 2000-01-27 2001-01-16 Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem. TR200401142T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17843800P 2000-01-27 2000-01-27
US22405800P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
TR200401142T4 true TR200401142T4 (tr) 2004-07-21

Family

ID=26874307

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01142T TR200401142T4 (tr) 2000-01-27 2001-01-16 Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem.

Country Status (17)

Country Link
US (4) US7598222B2 (tr)
EP (1) EP1257577B1 (tr)
JP (1) JP2003523366A (tr)
KR (1) KR20020073184A (tr)
AT (1) ATE264870T1 (tr)
AU (1) AU2001232735A1 (tr)
BR (1) BR0107837A (tr)
CA (1) CA2396920A1 (tr)
DE (1) DE60102899T2 (tr)
DK (1) DK1257577T3 (tr)
ES (1) ES2218381T3 (tr)
HU (1) HUP0204281A3 (tr)
IL (2) IL150913A0 (tr)
MX (1) MXPA02007231A (tr)
PT (1) PT1257577E (tr)
TR (1) TR200401142T4 (tr)
WO (1) WO2001055213A2 (tr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP4543236B2 (ja) * 2003-03-28 2010-09-15 独立行政法人農業生物資源研究所 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
ATE529126T1 (de) * 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
AU2004318013B8 (en) * 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
WO2006054696A1 (ja) 2004-11-19 2006-05-26 Mitsui Chemicals, Inc. エチレン系重合体微粒子、官能基含有エチレン系重合体微粒子およびその製造用触媒担体
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
TWI448326B (zh) 2005-04-07 2014-08-11 Mitsui Chemicals Inc 烯烴系聚合體所構成之膠囊狀微粒子
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
CA2622608C (en) * 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) * 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
ATE507235T1 (de) * 2006-02-08 2011-05-15 Lonza Ag Synthese von glucagon-ähnlichen peptiden
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
AR062760A1 (es) * 2006-09-13 2008-12-03 Takeda Pharmaceutical Administracion de inhibidores de dipeptidilpetidasa
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2749099A1 (en) 2009-01-08 2010-07-15 Mannkind Corporation Method for treating hyperglycemia with glp-1
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
IN2014DN03093A (tr) 2011-10-24 2015-05-15 Mannkind Corp
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
SG10201708090TA (en) 2013-03-15 2017-11-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
IL296682A (en) 2015-12-23 2022-11-01 Amgen Inc A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
WO2019120480A1 (en) 2017-12-19 2019-06-27 Novo Nordisk A/S Solubility of glp-1 peptide
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
WO2022266927A1 (zh) * 2021-06-24 2022-12-29 深圳翰宇药业股份有限公司 一种利拉鲁肽变构体及其制备方法、应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3419824A1 (de) * 1984-05-26 1985-11-28 Bayer Ag, 5090 Leverkusen Verfahren und formwerkzeug zum herstellen von formteilen mit grill-, gitter- oder rostartigen bereichen, wie kfz-soft-faces, spoiler, bumper, aus einer fliessfaehigen masse
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69918070T2 (de) * 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue

Also Published As

Publication number Publication date
HUP0204281A3 (en) 2007-03-28
US20110053838A1 (en) 2011-03-03
IL189371A0 (en) 2008-06-05
ATE264870T1 (de) 2004-05-15
EP1257577A2 (en) 2002-11-20
DK1257577T3 (da) 2004-08-02
CA2396920A1 (en) 2001-08-02
HUP0204281A2 (hu) 2003-04-28
US20120208980A1 (en) 2012-08-16
ES2218381T3 (es) 2004-11-16
IL150913A0 (en) 2003-02-12
US8268780B2 (en) 2012-09-18
WO2001055213A2 (en) 2001-08-02
US20030060412A1 (en) 2003-03-27
US20130072658A1 (en) 2013-03-21
US8455433B2 (en) 2013-06-04
AU2001232735A1 (en) 2001-08-07
BR0107837A (pt) 2003-01-14
KR20020073184A (ko) 2002-09-19
EP1257577B1 (en) 2004-04-21
US7598222B2 (en) 2009-10-06
US20120101034A9 (en) 2012-04-26
JP2003523366A (ja) 2003-08-05
PT1257577E (pt) 2004-08-31
MXPA02007231A (es) 2002-12-09
DE60102899D1 (de) 2004-05-27
WO2001055213A3 (en) 2002-02-28
DE60102899T2 (de) 2005-03-31
US8222205B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
TR200401142T4 (tr) Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem.
GEP20063860B (en) Chemically-modified human growth hormone conjugates
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
BR0114576A (pt) Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto
NZ515301A (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
DE60233722D1 (de) Insulinvorstufen und verfahren zu deren herstellung
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
DE60036924D1 (de) 5-ht1f agonisten
RS91204A (en) Lyophilized and liquid preparation comprising a polysaccharide derivative of camptothecin
AR009582A1 (es) Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato
IT1319674B1 (it) Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
HK1040237A1 (en) Fused polycyclic amino acids as pharmaceutical agents.
NL8302935A (nl) Nieuwe polypeptiden, werkwijzen voor hun bereiding, farmaceutische preparaten die deze polypeptiden bevatten en hun toepassing.
CY1106051T1 (el) ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ Ν-ΠΡΟΣΤΑΤΕΥΜΕΝΩΝ ΑΖΕΤΙΔΙΝΟ-2-ΚΑΡΒΟΞΥΛΙΚΩΝ ΟΞΕΩΝ (AzeOHs)
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
DE602005011797D1 (de) Aufreinigung von n-(phosphonomethyl)glycin
SE8704832L (en) Prepn. for dissolving caries - comprises nitrogen-contg. cpds. and sodium hypochlorite
ECSP992942A (es) Estimulacion hematopoyetica
DE60228448D1 (de) Verfahren zur herstellung von aminostilbenderivaten
ES2156037B1 (es) Sales de aminoacidos solubles en disolventes organicos y su uso en la preparacion de dipeptidos.
CY1114355T1 (el) Υδατοδιαλυτα αλατα στροντιου για χρηση στην θεραπεια των παθησεων του χονδρου ή/και των οστων
RS32304A (en) Novel betha-phenyl-alpha- oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds